July 2016

Crack GPAT — Prepare for GPAT Online 
15 July 2016
Job for Pharm.D/B.Pharm as Senior Scientific Specialist in PAREXEL

PAREXEL has supported the Bio-Tech and Pharmaceutical industries in helping the development of new drugs and treatments on a global basis. As a leading global biopharmaceutical service provider, they supply knowledge-based contract research, medical communications and consulting services across a broad range of therapeutic areas to the worldwide pharmaceutical, biotechnology and medical device industries. They have helped over 800 clients to develop and launch some of the most important drugs and devices of our time-helping people live better and healthier lives everywhere in the world. Headquartered near Boston, Massachusetts, PAREXEL operates in more than 50 countries around the world.

Post:  Senior Scientific Specialist

15 July 2016
Walk in interview in Production, Regulatory Affairs, Product Development at Apotex Research

Apotex Research Pvt. Ltd. is a wholly owned subsidiary of Apotex Inc. Canada which is a number one generic pharma co. in Canada. The position is for Bangalore location which has an R&D Centre, Manufacturing and a Bioequivalence Centre.

Post: Manager, Pharmacist, Team Leader, Technicians, Research Scientist

15 July 2016
Walk in interview at DIPAS for Post of Research Associate(01 Post) and Junior Research Fellows(06 Posts)

Defence Institute of Physiology and Allied Sciences (DIPAS) provides an excellent opportunity for young and motivated researchers to pursue a career in basic and applied Life Sciences research. Defence Institute of Physiology and Allied Sciences (DIPAS) provides an excellent opportunity for young and motivated researchers to pursue a career in basic and applied Life Sciences research. DIPAS endeavors in optimizing human performance under extreme operational environments using physiological, biochemical, nutritional and ergonomic approach. The labs are equipped with state-of-art facilities to conduct human studies, animal and in-vitro experimentation with an interdisciplinary approach. Applications are invited from young and motivated candidates to work in ongoing and future research projects of DIPAS for the following posts:

Post : Junior Research Fellows, Research Associate

15 July 2016
Opening to work as Manager- Medical Scientific Liaison in Abbott

Abbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. With a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals, Abbott serves people in more than 150 countries and employs approximately 69,000 people.

Post:  Manager-Medical Scientific Liaison

15 July 2016
Wanted Project fellow at Malabar Cancer Centre

Malabar Cancer Centre, Thalassery (MCC) is an autonomous institution under Health and Family Welfare Department, Government of Kerala, started with an aim to establish a comprehensive cancer centre, providing the much-required oncology care to the population of Northern region of Kerala and neighbouring parts of Karnataka and Tamilnadu states. The main objective of the centre is not only to provide comprehensive cancer care but also to develop as a Research and Training Centre of international standards. A society named Malabar Cancer Centre Society was registered under Societies Registration Act XXI of 1860 with the above aims and clinical work in MCC started from March 2001 onwards. At present MCC has around 110 in-patient bed strength which is expected to be increased to 220 in near future.

Post : Project fellow

Loxo Oncology, Inc, a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to LOXO-101, a selective inhibitor of tropomyosin receptor kinase (TRK), “for the treatment of unresectable or metastatic solid tumors with NTRK-fusion proteins in adult and pediatric patients who require systemic therapy and who have either progressed following prior treatment or who have no acceptable alternative treatments.”

Amgen announced that the company will discuss data supporting the ABP 501 Biologics License Application (BLA) with the US Food and Drug Administration's (FDA) Arthritis Advisory Committee. ABP 501 is a biosimilar candidate to Humira (adalimumab), an anti-tumour necrosis factor-alpha (TNF-a) monoclonal antibody, which is approved in many regions for the treatment of several inflammatory diseases.